The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from bankruptcy proceedings tied to opioid litigation.

According to the 13 March announcement, the merger will create a “larger, more diversified entity”, with Mallinckrodt shareholders holding a 50.1% stake and Endo shareholders receiving 49.9% ...

following the close of the merger agreement. Mallinckrodt and Endo said the location of the combined company’s U.S. headquarters and its corporate name will be announced “in due course.” ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...

(Reuters) -Mallinckrodt and Endo, drugmakers which recently emerged ... the companies said on Thursday. The merger transforms two companies, previously at risk of closure due to declining revenue ...